COVID-19
As COVID-19 surges to earlier pandemic levels in the U.S., federal health officials are expected to authorize a third booster shot eight months after receiving the second of the Moderna and Pfizer-BioNTech vaccines, and probably the Johnson & Johnson vaccine as well.
As the COVID-19 pandemic continues with surges in the U.S. in unvaccinated people, biopharma companies are still working on new vaccines and therapies against the disease.
By administering a vaccine directly into the nasal cavity, the mucus membranes of the nose and throat would provide better protection than the intramuscular alone.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
The Phase II study showed that the asset achieved antiviral activity in healthy patients and set the stage for AT-527’s potential as a preventative treatment for COVID following exposure to the virus.
The amended EUA is aimed at patients who have undergone solid organ transplants or those diagnosed with conditions that have an “equivalent level of immunocompromised.”
COVID-19 probably can be eradicated globally, just like polio, according to research just published in BMJ Global Health. That assumes, however, that a high rate of vaccination occurs globally and that there is a quick response to emerging variants.
Citing a study from Johns Hopkins University, researchers found that immunocompromised people are 485 times more likely to end up in the hospital or die from COVID-19.
I-Mab announced positive interim data from its U.S. Phase II/III clinical trial of plonmarlimab for treatment of cytokine release syndrome in severe COVID-19.
Women who are pregnant are more vulnerable to developing severe illness after infection with SARS-Cov-2, the novel coronavirus that causes COVID-19.
PRESS RELEASES